By Yosef Shiloh
ESI Special Topics,
July 2004
Citing URL - http://www.esi-topics.com/nhp/2004/july-04-YosefShiloh.html
|
Yosef Shiloh answers a few questions about this month's
new hot paper in the field of Clinical Medicine.
From
•>>July 2004
Field:
Clinical Medicine
Article Title: ATM and related protein kinases: Safeguarding genome integrity
Authors: Shiloh, Y
Journal: NAT REV CANCER
Volume: 3
Page: 155-168
Year: MAR 2003
* Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.
* Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.
|
Why
do you think your paper is highly cited?
|

“We now understand the chain of events that leads to instantaneous activation of the enormous cellular response to DNA lesions”
|
|
This paper is a review, and reviews tend to be highly cited. But
there is probably more to it than that. The paper deals with a central
subject in biomedical research: the cellular responses to DNA damage.
These responses are essential for maintaining the genomic stability
and integrity essential for preventing cellular death or malignant
transformation. Defects in this system lead to a variety of very
severe diseases. Thus, this field is of great interest to basic
scientists as well as to clinicians from many areas of medicine.
Does
it describe a new discovery or new methodology that's useful to
others?
The paper summarizes several new concepts that have emerged
recently in this rapidly evolving field, and sums up the significant
advances in our understanding of the complex network of processes
that respond to DNA damage. Several of the major players in this
response are potential targets for cancer therapy, making this
information useful to cancer researchers and oncologists. On the
other hand, the degenerative nature of genetic disorders associated
with defects in the DNA damage response attracts the attention of
investigators and physicians in areas such as neurology, immunology,
gerontology, and public health.
Could
you summarize the significance of your paper in layman's terms?
Our genetic material, the DNA, which is contained in the nucleus
of every cell of our body, is constantly under attack from physical
and chemical agents that cause a variety of DNA lesions. While some
of these agents are external, many are formed within the cell as
by-products of normal metabolism. A sophisticated system has evolved
to respond to these lesions—an intricate network that includes DNA
repair machinery and numerous other stress responses that help the
cell maintain metabolic equilibrium while its normal life cycle is
temporarily halted to allow DNA repair to take place. Defects in
this system lead to severe genetic disorders involving tissue
degeneration, sensitivity to specific damaging agents, genomic
instability, and cancer predisposition. Furthermore, subtle defects
in the DNA damage response probably underlie certain chronic
diseases, cancer predisposition in the general population, and
differences in the pace at which individuals age. Recent progress in
our understanding of the DNA damage response has led to the
discovery of many of the central players in this system. We now
understand the chain of events that leads to instantaneous
activation of the enormous cellular response to DNA lesions. This
system is turning out to be a prime example of cellular signal
transduction.
How
did you become involved in this research?
My involvement in this field stems from my long-term interest in
a devastating human
genetic disorder called ataxia-telangiectasia (A-T), an interest that
began when I was a graduate student some 27 years ago and met a family
with A-T. The striking phenotype of the patients led me to make the
disease the subject of my Ph.D. thesis and I have
remained in A-T research ever since. A-T is caused by a defect in the
cellular response to a specific type of DNA lesion—the double-strand
break. This is the most critical DNA lesion caused by ionizing
radiation. A-T patients suffer from neurodegeneration,
immunodeficiency, radiation sensitivity, genomic instability, and
cancer predisposition. In 1995, our lab in Tel Aviv identified the
defective gene that leads to A-T, and called it ATM (A-T, Mutated). We
then shifted gears from molecular genetics to protein chemistry and
began studying the ATM protein, the product of the ATM gene, in order
to understand the physiological basis of A-T. Work in our lab and many
other labs has elucidated the role of the ATM protein as the chief
regulator and mobilizer of the cellular responses to DNA double-strand
breaks. We now understand how one protein, ATM, can stir such a wide
chain of reactions, sometimes in response to very few or even a single
double-strand break in the DNA!
Yosef Shiloh, Ph.D.
Professor of Human Genetics
David and Inez Myers Professor of Cancer Genetics
Department of Human Genetics and Molecular Medicine
Sackler School of Medicine
Tel Aviv University
Tel Aviv, ISRAEL
|
ESI Special Topics,
July 2004
Citing URL - http://www.esi-topics.com/nhp/2004/july-04-YosefShiloh.html
|
|
|